Elite Pharmaceuticals INC /NV/ 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Elite Pharmaceuticals Inc. announced a significant increase in revenue for the fiscal year ended March 31, 2026, driven by new product launches and expanded sales.
OQB
10-K: Elite Pharmaceuticals Reports Strong Revenue Growth Amidst Net Loss and Intangible Asset Impairments
Elite Pharmaceuticals, Inc. announced a 48% increase in total revenue to $84.0 million for the fiscal year ended March 31, 2025, primarily due to four new product launches and increased sales from its Elite Label product line, though the company reported a net loss of $4.3 million and identified material weaknesses in internal controls.
OQB
Elite Pharmaceuticals, Inc. reports a significant 66% increase in revenue for fiscal year 2024, driven by the launch of its own label products.